Pharma stocks zoom: Laurus Labs, Aurobindo hit new highs in trade
BSE is in focus.
· Business Standard Mkts
The BSE Healthcare index rallied over 1% in Monday's trade. Thus far in the financial year 2026-27, it outperformed the market by soaring 25%, against a near 4% rise in the BSE Sensex.
The analysis
BSE reported movement of 1%, 4% and 25%. Those are the figures as filed — what moves the price is how they sit against what the market already expected, not their absolute size.
Because the driver here is macro rather than company-specific, the read-through is to index-level positioning rather than to any single name — correlations tend to rise when the whole market faces the same signal.
Why it matters
- With BSE involved, this carries a regulatory dimension that can outlast the immediate market reaction.
Market context
- This is a market-wide development — its reach goes beyond any single stock.
- Sector exposure: Pharma & Healthcare.
- The immediate tone of coverage reads positive.
In this story
Related coverage
Stock Market Crash LIVE: Sensex Tanks Over 1,200 Points, Nifty 50 Below 22,200; ITC, JSW Steel, IndiGo Among Top Losers
INR vs USD: Rupee near 97/dollar; how TCS, Sun Pharma, Tata Steel, SRF may gain from weaker currency? Experts explain
Pharma stocks to buy ahead of Q2 results: Acutaas Chemicals, Mankind Pharma, Ipca Labs - Max upside? Target price
Sun Pharma to consider ₹15,000 crore NCD issue; board meeting on 12 October
Valiant Organics among 5 commodity stocks that hit 52-week highs and rallied up to 48% in a month